Fennec制药 FENC 深 沪
等待开盘 05-18 09:30:00 美东时间
9.75
+0.510
+5.52%
华盛通- 最 高10.1699
- 今 开9.29
- 成交量 60.26万股
- 最 低 9.17
- 昨 收 9.24
- 总市值 3.38亿
- 52周最高 10.1699
- 市盈率 静 --
- 换手率 1.74%
- 52周最低 5.65
- 委 比 -62.22%
- 总股本 3471.28万
- 历史最高 14.986
- 量 比 1.04
- 振 幅 10.82%
- 历史最低 3.255
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 股价狂飙超68%！AI芯片新星Cerebras首日表现惊艳；光通信牛股POET涨超43%
股价狂飙超68%！AI芯片新星Cerebras首日表现惊艳；光通信牛股POET涨超43%，此前披露光引擎采购大单；无人机公司ONDS涨逾26%，Q1营收同比暴增逾十倍>>
05-15 19:10
Fennec Pharmaceuticals shares are trading higher. The company reported Q1 financial results.
Fennec Pharmaceuticals shares are trading higher. The company reported Q1 finan...
05-15 03:30
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) released first-quarter financial results a...
05-14 21:32
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand Overview US specialty pharma's Q1 product sales rose 73% yr/yr on higher PEDMARK adoption Company posted net income of $201,000, reversing a loss a year ago Growth driven by expanded field sales and increased demand for PEDMARK Outlook Compa
05-14 18:41
Fennec Pharmaceuticals Q1 EPS $0.01 Beats $(0.02) Estimate, Sales $15.108M Beat $13.954M Estimate
Fennec Pharmaceuticals (TSX:FRX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. This is a 125 percent increase over losses of $(0.04) per share from
05-14 18:38
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
Fennec Pharmaceuticals Inc. will release its Q1 2026 financial results on May 14, 2026, before U.S. markets open. A conference call and webcast at 8:30 a.m. ET will discuss the results. The webcast can be accessed via www.fennecpharma.com. Fennec, focused on reducing ototoxicity in cancer patients, commercializes PEDMARK®. It received FDA approval in 2022 and European Commission approval in 2023. In 2024, Fennec partnered with Norgine for PEDMARQ...
05-07 10:36
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target
Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.
04-16 21:29
Fennec Pharma Initiates Investigator-Sponsored Study By University Of Arizona Cancer Center To Evaluate Use Of PEDMARK In Adolescent And Young Adult And Adult Patients With Head And Neck And Testicular Cancers Receiving Cisplatin
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~~ This New Study and Other Independent, Institution-Led Research
04-07 19:12
